Zenas BioPharma (ZBIO) FCF Margin (2024 - 2026)

Zenas BioPharma (ZBIO) posted quarterly FCF Margin of 370.69% for Q1 2025, up 52.02% quarter-over-quarter from 772.56% in Q4 2024.

Zenas BioPharma (ZBIO) FCF Margin (2024 - 2026) Analysis & Trends

Zenas BioPharma's FCF Margin history runs 2 years deep, the most recent figure standing at 370.69% for Q1 2025.

In Q1 2025, FCF Margin changed N/A year-over-year to 370.69%; the TTM figure through Dec 2025 stood at 1723.51% (up 67259.0% YoY), while the FY2025 annual figure was 1723.51%, up 67259.0% from the prior year.
FCF Margin for Q1 2025 stood at 370.69%, up from 772.56% in the prior quarter.
The five-year high for FCF Margin was 370.69% in Q1 2025, with the low at 772.56% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	13.35%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,594.17%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	70.82%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.62%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-22.35%
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-	-5,723.70%

Download Data